The Globe and Mail - The Globe and Mail
Where Arrowhead Pharma Stands With Analysts - Arrowhead Pharma (NASDAQ:ARWR) - Benzinga
TDR's U.S. Stock Market Preview For The Week Of November 28, 2022 - The Dales Report
ARWR: Phase 1/2a Clinical Trials Underway for Pulmonary Disease Candidates… - Arrowhead Pharma (NASDAQ:ARWR) - Benzinga
Want Diversified Upside in Biotechnology? Check out LABU | Nasdaq
Zacks Small-Cap Research
ARWR Institutional Ownership and Shareholders - Arrowhead Pharmaceuticals Inc. (NASDAQ) Stock
joetrader (@joetrader87) / Twitter
Zacks Small-Cap Research
ARWR / Arrowhead Pharmaceuticals Inc - Put/Call Ratio, Options Sentiment, Unusual Options Activity
ARWR / Arrowhead Pharmaceuticals Inc - Put/Call Ratio, Options Sentiment, Unusual Options Activity
Arrowhead Pharmaceuticals Long-Term Intact As Shorts Finish Taking Profits (NASDAQ:ARWR) | Seeking Alpha
Arrowhead Pharmaceuticals Inc (ARWR) Stock Holders - Institutional & Insider Ownership | GuruFocus
ARWR | Arrowhead Pharmaceuticals Corp. Stock Overview (U.S.: Nasdaq) | Barron's
SEC Filing | Arrowhead Pharmaceuticals Inc.
joetrader (@joetrader87) / Twitter
After a year of 4.1% returns, Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) share price drop last week may have less of an impact on institutional investors
Arrowhead Pharmaceuticals Remains A Buy For Pipeline Potential (NASDAQ:ARWR) | Seeking Alpha
Losing in Afghanistan | Foreign Affairs
Arrowhead Pharmaceuticals Short Interest Ratio and Volume (NASDAQ:ARWR)
ARWR | Arrowhead Pharmaceuticals Corp. Stock Overview (U.S.: Nasdaq) | Barron's
ARWR | Arrowhead Pharmaceuticals Corp. Stock Overview (U.S.: Nasdaq) | Barron's
Intellia Therapeutics Short Interest Ratio and Volume (NASDAQ:NTLA)
Arrowhead Pharmaceuticals' Short Interest Declines in May 2023 - Best Stocks
Stock Forecast Based On a Predictive Algorithm | I Know First |Algorithmic Trading Strategy Based on Artificial Intelligence: Returns up to 82.13% in 3 Months
ARWR | Arrowhead Pharmaceuticals Corp. Stock Overview (U.S.: Nasdaq) | Barron's
Massive Increase In Short Interest Could Be Setting Bears Up For A Fall In Arrowhead Pharmaceuticals (NASDAQ:ARWR) | Seeking Alpha
